Sentences with phrase «disorders of the central nervous system»

For example, MethylGene Inc. (TSX: MYG) is focusing on cancer treatment, biOasis Technologies Inc. (TSXV: BTI) is pursuing research on disorders of the central nervous system, and Cipher Pharmaceuticals Inc. (TSX: DND) is working on a treatment for acne - related conditions.

Hear the story behind Backstage Capital Headliner Novoron Bioscience, a San Diego - based biotech company developing novel therapeutic approaches to address disorders of the central nervous system.

Palm Oil - Derived Natural Vitamin E a-Tocotrienol in Brain Health and Disease: Scientific literature evaluating the therapeutic potential of tocotrienols (type of vitamin E found in abundance in palm fruit oil) for neurodegenerative disorders of the central nervous system, cancer treatment, and hypercholesterolemia.

In the past researchers have observed an association between poor mitochondrial function and Parkinson's disease, a neurodegenerative disorder of the central nervous system that impairs speech and motor functions and affects five million people worldwide.

It could also lead to the development of new therapies against other more common neurodegenerative disorders of the central nervous system, as well as diseases related to the propagation of pathological proteins, including Parkinson's and Alzheimer's.

«Our research should stimulate renewed clinical interest in developing glucocorticoid therapies to treat blast - induced traumatic brain injury (bTBI) and other disorders of the central nervous system,» Morrison says.

That can help us both recognize fibromyalgia for what it is — a disorder of the central nervous system — and treat it more effectively.»

The N2B patch project is supported financially by the EU within the scope of the tender procedure «Biomaterials for diagnosis and treatment of demyelination disorders of the central nervous system.»

Parkinson's disease is a degenerative disorder of the central nervous system that causes a person to lose control of motor movements, such as the ability to move his or her hands, arms, and legs.

The study of almost 8,000 families, published today (21 March) in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

Grillner had severed the cats» spines, rendering them paralyzed, and then injected them with an amino acid called L - dopa, routinely used to treat Parkinson's disease — a neurodegenerative disorder of the central nervous system characterized by motor symptoms.

Epilepsies are amongst the most common disorders of the Central Nervous System, affecting up to 50 million patients in worldwide.

An autoimmune disease, MS is an unpredictable and potentially debilitating disorder of the central nervous system that affects more than two million people worldwide.

The study of almost 8,000 families, published in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

Treatment of disorders of the central nervous system including malignant, benign and functional diseases, Stereotactic radiosurgery (SRS) via both Gamma Knife and Linear Accelerator platforms, Stereotactic ablative radiation (SABR), Proton Beam Therapy (PBT), External beam radiation therapy (EBRT), Intensity - modulated radiation therapy (IMRT), Volumetric arc therapy (VMAT), Image - guided radiation therapy (IGRT)

Niemann - Pick disease is a rare and fatal disorder of the central nervous system (the brain and spinal cord) that has no cure.

They have also been linked to disorders of the central nervous system including anxiety, depression, autism and multiple sclerosis, which may be a consequence of an ecosystem that has fallen out of balance.

Similarly, altered zinc levels in plasma, enzymes and neurons have been demonstrated in a number of disorders of the central nervous system (Ebadi et al. 1995).

Epilepsy is a disorder of the central nervous system.

Adamas Pharmaceuticals Inc is a specialty pharmaceutical company, is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems.

Adamas Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems.

Some clinical studies have also established the clinical usefulness of probiotic bacteria in the management of certain disorders of the central nervous system.

Cerebral palsy, also known as Little's disease, is a disorder of the Central Nervous System.

Parkinson's disease is a degenerative disorder of the central nervous system named for James Parkinson (1755 - 1824), the physician who first described it in 1817.

Not exact matches

The company runs clinical studies on behalf of its multinational pharma clients in oncology, respiratory / infectious disease and central nervous system disorders.

Analysts point to three main therapeutic areas — cancer, central nervous system disorders (such as Alzheimer's, depression and pain), and cardiovascular disease — as core strengths of Canada's biopharmaceutical research industry.

One day, Reynolds says, a version of InVivo's implant, packed with stem cells or hormones, might help the six million Americans who are chronically paralyzed from SCI and other central nervous system disorders improve their level of functioning.

The disease is characterized by the accumulation of very long chain fatty acids (VLCFA) leading to a neurodegenerative disorder that is chronically debilitating and life - threatening, where the most affected tissues are the myelin in the central nervous system (CNS) and the adrenal cortex.

Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease / nonalcoholic steatohepatitis.

The clinical - stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life - altering central nervous system (CNS) disorders, SAGE Therapeutics Inc. (NASDAQ: SAGE) seem to be poised for a price surge as per its latest charts.

This would impact a range of funding areas, including research on kidney and lung disorders, digestive diseases, central nervous system injuries, and sensory loss.

A team of researchers at the University of Central Florida is using breakthrough gene - editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system.

The vectors are customizable and could potentially be used as part of a gene therapy to treat neurodegenerative disorders that affect the entire central nervous system, such as Huntington's disease, or to help map or modulate neuronal circuits and understand how they change during disease.

Neurofibromatosis is one of at least 60 genetic diseases called neurocutaneous disorders that involve the skin, central nervous system, and / or peripheral nervous system, according to a comprehensive review article in the journal Current Neurology and Neuroscience Reports by neurologists at Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine.

According to Miller, «This work suggests that enhanced vesicular filling can be sustained over time and may be a viable therapeutic approach for a variety of central nervous system disorders that involve the storage and release of dopamine, serotonin, or norepinephrine.»

A team of international scientists led by Baylor College of Medicine has discovered a novel gene (CLP1) associated with a neurological disorder affecting both the peripheral and central nervous systems.

A newly identified genetic disorder associated with degeneration of the central and peripheral nervous systems in humans, along with the genetic cause, has been discovered by researchers.

A newly identified genetic disorder associated with degeneration of the central and peripheral nervous systems in humans, along with the genetic cause, is reported in the April 24, 2014 issue of Cell.

«And many studies of the brain and central nervous system, using imaging, EEG and other objective measures of brain structure and function, add to the existing evidence that central nervous system dysfunction is a critical element in the disorder.

Ritalin, the brand name for methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder, is a growing problem among college students who use it without a prescription as a so - called «study enhancer.»

Such a system will enable ethical and more rapid and accurate testing of experimental drugs before the clinical trial stage and advance studies of genetic and environmental causes of central nervous system disorders.

Multiple sclerosis (MS) is among the most common neurological diseases in young adults, affecting 350 000 individuals in the United States and 2 million worldwide.1 Prevailing thought is that MS is an autoimmune disorder whereby an unknown agent or agents triggers a T cell — mediated inflammatory attack, causing demyelination of central nervous system tissue.2

«We are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness,» said Bioquark CEO Ira Pastor.

Most recently, Dr. Gringeri was the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a Netherlands - based company engaged in human gene therapies for orphan diseases related to metabolic disorders, liver diseases, blood diseases, and disorders of the central and peripheral nervous systems.

In the fall of 2012, their group demonstrated that misfolded versions of α - synuclein, the protein implicated in Parkinson's disease, can be transmitted from cell to cell in mouse models, adding weight to a hypothesis that a common mechanism of neurodegenerative disorders could involve the passage of misfolded proteins through the central nervous system.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Simply put, both disorders prevent normal development of the central nervous system, resulting in premature death in children, presenting an urgent need for effective therapeutic intervention.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria

Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.

Both MPS IIIA and GM1 are classified as neuropathic (i.e. affecting the central nervous system) Lysosomal Storage Disorders, a group of approximately 50 rare inherited metabolic disorders that result from defects in lysosomal function.